Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$70.34 USD
+0.20 (0.29%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $70.34 0.00 (0.00%) 6:20 PM ET
4-Sell of 5 4
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARS 70.34 +0.20(0.29%)
Will TARS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for TARS
Slingshot Bullish appears for TARS after 0.34% move
TARS makes New 52 Week Closing High on October 9
Tarsus Pharmaceuticals price target raised to $85 from $80 at BofA
Tarsus Pharmaceuticals price target raised by $5 at BofA, here's why
New 52 Week Closing High appears for TARS after 1.94% move